Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Increases By 65.4%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 1,720,000 shares, a growth of 65.4% from the June 15th total of 1,040,000 shares. Approximately 6.7% of the shares of the company are sold short. Based on an average trading volume of 5,530,000 shares, the short-interest ratio is currently 0.3 days.

Allarity Therapeutics Price Performance

Shares of Allarity Therapeutics stock opened at $0.20 on Friday. Allarity Therapeutics has a 1-year low of $0.19 and a 1-year high of $69.00. The business’s fifty day moving average price is $0.48 and its two-hundred day moving average price is $4.69.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($22.14) EPS for the quarter. On average, analysts predict that Allarity Therapeutics will post -2.6 EPS for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.